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Background: After years of disuse of chloroquine (CQ) as first-line anti-malarial drug in Ghana, reports from
molecular studies conducted in parts of the country indicate varying prevalence of T76 mutation in the pfcrt gene.
This situation has several health implications, one being that mutations that confer resistance to CQ have been
reported to show substantial cross-resistance to other anti-malarial drugs. It is important to identify some of the
factors contributing to the continuous presence of CQ resistance markers in the country. This study determined
the prevalence of T76 mutation in pfcrt gene of Plasmodium falciparum isolates collected from selected areas of
the Central region of Ghana and correlated with the level of CQ use in these areas.
Methods: Plasmodium falciparum DNA was extracted from collected blood-blot filter paper samples in the study
sites. The prevalence of T76 point mutation in pfcrt gene was assessed using nested PCR followed by RFLP.
CQ from pharmacy and chemical shops was obtained using mystery buying method. The extent of CQ use by
the participants was determined by measuring the level of the drug in their urine samples using the Saker-Solomon
method.
Results: Of the 214 P. falciparum isolates analysed, 71.9% were found to have T76 mutation of pfcrt gene. The study
revealed that 14.49% of community pharmacies and chemical shops had stocks of CQ for sale while 16.9% of the
participants had CQ in their urine samples. There is five times more risks of becoming infected with CQ resistant
strain for staying in an area where CQ is stocked for sale [RR = 0.20, p < 0.0001] and thirteen times more risks of
having CQ-resistant mutant from those who still use CQ than non-users [OR = 0.08, p < 0.0001].
Conclusion: This study has shown that high variation in the prevalence of T76 mutations of P. falciparum is linked
with the level of CQ stocking and usage within study area.
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Undeniably, anti-malarial drug resistance remains a major
obstacle to malaria control in the disease endemic areas.
Based on reports of high chloroquine (CQ) treatment fail-
ure in Ghana and the recommendations of the World
Health Organization (WHO) [1-3], CQ was replaced with
artemisinin-based combination therapy (ACT) in 2004.
Interestingly, high prevalence of CQ resistant mutants* Correspondence: jonboamus@yahoo.com
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unless otherwise stated.have been reported in different parts of the country by
several researchers after the change in the malaria treat-
ment policy [4,5] though others have reported decreased
trend in prevalence and resistance in vitro [6,7].
Substitution of adenylate with cytidylate at position 76
of Pfcrt gene which changes lysine to threonine (K76 to
T76) is a single molecular marker that strongly correlates
with CQ drug resistance in Plasmodium falciparum in
most malaria endemic areas [8,9]. Similarly, other muta-
tions at different codons of pfcrt gene have also shown
association with CQ resistance [8,10,11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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by Duah and colleagues, they showed that there is
decrease in T76, although the prevalence varies from study
site to study site [6]. Earlier, Abruquah and colleagues had
reported 88.6% K76T prevalence in Kumasi [4], while
Kwansa-Bentum and colleagues reported 51.6% K76T
prevalence in southern part of Ghana [5]. A study con-
ducted in 2004 by Duah and colleagues reported different
T76 mutations among the various sentinel sites for their
studies [12]. In that study, they reported T76 prevalence to
be 80% at Hohoe, 46% at Navrongo, 98% at Tarkwa, 61% at
Sunyani & 46% in Yendi [12]. This study was conducted to
find out the prevalence of T76 mutation in the selected
health facilities and to determine the cause for the high
prevalence of CQ resistance.
Methods
Study sites
Samples for this study were collected from municipal
hospital (Cape Coast), district hospitals (Twifo Praso
and Assin Foso) and health centres (Elmina) all in the
Central region of Ghana. Cape Coast metropolis covers
an area of 122 square kilometres (sq. km) and is the
smallest metropolis in the country. The capital, Cape
Coast, is also the capital of the Central Region. Cape
Coast metropolitan hospital serves an average popu-
lation of 140,000 and receives a yearly attendance of
80,000 to 100,000 patients. It is located in Bakaano a
suburb of Cape Coast. Elmina is the district capital of
Komenda-Edina-Eguafo-Abirem (KEEA) and covers an
area of 1,372.45 square kilometres. The Elmina Urban
Health Centre caters for inhabitants of an area of 600
sq. km comprising 22 villages with catchment population
of about 50,000. Twifo Praso is the district capital of the
Twifo-Heman-Lower Denkyira district. The district covers
an area of 1,199 square km with about 1,510 settlements.
Twifo Praso Government hospital is a district hospital.
It a serves catchment population of 15,351, distributed in
Twifo Praso and neighbouring towns. The Assin North
district covers an area of about 1,500 sq. km. and com-
prises about 1,000 settlements. The St. Francis Xavier
Hospital still remains the District Hospital for both Assin
north and Assin south districts covering a land mass of
1,255 sq. km (1/4) of Central Region. The hospital has
catchment population of 207,000.
Ethical considerations
The study was approved by the Ghana Health Service
Ethics Committee (GHS-ERC-17/01/12) and University
of Cape Coast Institutional review Board (UCCIRB/28/
09/3.1.1). Approval was also sought from the Medical
directors and administrators of the various health facilities
before sample collection. Anonymity of study subjects was
strictly enforced. Samples were collected and handledsolely by trained laboratory technologists. The study posed
no risk to participants except for the transient pain they
felt during blood collection. Sterile techniques were em-
ployed using disposable new materials at all times.
Recruitment of participants
The study was explained to the prospective participants
who were referred to the laboratory for malaria test.
Informed consent was sought from those who satisfied
the inclusion criteria and agreed to be part of the study.
A patient was included into the study if he/she was older
than six months old, had Plasmodium parasitaemia, was
conscious, non-haemophilic, and did not experience
palpitation at the time of sample collection.
Sample collection
One millilitre (1 ml) of blood sample was collected from
each participant into tubes containing EDTA by trained
and licensed medical laboratory technologists from the
health facilities. Also 10 ml mid stream urine samples
were collected at the time of participant visit for CQ
analysis. All samples collected were stored on ice and
transported to the Parasitology Research Laboratory of
the Department of Biomedical and Forensic Sciences,
University of Cape Coast where they were stored at-20°C.
About six drops of blood sample collected was spotted on
a 3MM Whatman filter paper. The blood spots were air-
dried and stored at -20°C in zip-locked plastic envelopes
containing silica gel.
Detection of pfcrt polymorphisms
DNA was extracted from the perforated portions of blood
spotted filter-paper using chelex extraction method [13].
PCR followed by restriction fragment length polymorph-
ism (RFLP) was used to detect the mutations following
published protocols [14]. The primers for the DNA ampli-
fication of pfcrt are shown in Table 1.
Mystery buying of CQ
Mystery buyers were used to investigate if Chemical shops
and Community Pharmacies in these communities still
stocked CQ using convenient sampling method. Surrogate
buyers visited chemical and pharmacy shops located in
the study areas to buy CQ.
Urine CQ assay
The specific gravity of urine samples were determined
using urinometer (BD Adams TH, Canada). The presence
of CQ in the participants’ urine was detected with Saker-
Solomon’s method [15]. A standard curve was estimated
from standard concentrations (0, 2, 3, 4, or 5 μg/ml) of CQ
(Sigma-Aldrich, UK). The presence of CQ in the urine
samples that tested positive to Saker-Solomon method was
determined spectrophotometrically. In the Saker-Solomon
Table 1 Oligonucleotide sequence and PCR conditions used to detect PfcrtK76T SNP
Primer Sequence (5' - 3') Size (bp) PCR condition
Primary amplification
CRT1F TTGTCGACCTTAACAGATGGCTCAC 526 96°C, 15’ followed by 45X (96°C, 30”; 56°C, 90”; 72°C, 90”); 72°C, 10’
CRT1R AATTTCCCTTTTTATTTCCAAATAAGGA
Nested amplification
CRT2F CTTGTCTTGGTAAATGTGCTC 200 96°C, 15’ followed by 45X (96°C, 30”; 50°C, 90”; 72°C, 90”); 72°C, 10’
CRT2R GAACATAATCATACAAATAAAGT
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sample was added to a well in triplicates. The absorbance
of the urine samples was read at 565 nm. The concentra-
tions were determined from the standard curve. A stand-
ard CQ concentration which corresponds to each of the
urine samples was also prepared read at 565 nm. The
cross-reactivity for each sample was then determined using
the formula; Absorbance of Urine sample/Absorbance CQ
standard. The urine samples that tested positive qualita-
tively to Saker-Solomon’s urine CQ method but the sam-
ples whose error margins fell below or above 5% error
margin were considered to be cross-reacting with other
compounds (such quinine) after estimating the ratios of
absorbance of samples to absorbance of standards of equal
concentrations.
Data analysis
Data were entered and validated using Microsoft Office
Excell® 2007 (Microsoft Corporation) and analysed with
SPSS® Statistical Software version 16 (SPSS Inc.) and
MedCalc® statistical software version 12.7.2 (MedCalc
software, Ostend, Belgium). The count of samples with
mutant and wild-type alleles was used to generate the
prevalence of the alleles. Pearson chi-square test and
relative risk were used to compare the risks of becoming
infected with CQ-resistant P. falciparum when one stays
in an area where pharmacies and chemical shops stock
CQ. Pearson chi-square test and Odd ratio were also
used to compare the risks of the use CQ and becoming
infected with CQ-resistant P. falciparum strains. The
Pearson chi-square test was used to determine the asso-
ciation between the alleles and CQ stock and CQ usage.Table 2 Prevalence of subjects that still use CQ and the drug








n represent the number of subjects that had CQ in their urine.
N represent the total number of subject whose urine were tested for CQ.Results
A total of 444 participants had their urine successfully
examined for the presence of CQ in this study; 56 from
Cape Coast, 105 from Elmina, 143 from Assin Foso and
140 from Twifo Praso. The corresponding prevalence of
patients with detectable CQ in their urine per the study
sites were 23.21%, 11.43%, 18.88% and 16.43% respect-
ively. In all, 75 of participants had CQ in their urine
representing 16.89% prevalence of CQ consumption in
the four study areas. The total prevalence of CQ stocks
within the four study areas were 14.49% (10/69); 21.05%
(4/19) in Cape Coast, 9.09% (1/13) in Elmina, 16.67%
(3/19) in Assin Foso and 10.53 (2/19) in Twifo Praso
(Table 2).
Two hundred and fourteen (214) of the P. falciparum
isolates had DNA extracted and analyzed for pfcrt T76
mutant allele. Fifty six (56) of the isolates were from
Cape Coast, 52 from Elmina, 54 from Assin Foso and 52
from Twifo Praso. The overall prevalence of pfcrt T76
mutation was 71.96% (154/214); 80.4% in Cape Coast,
78.8% in Elmina, 75.9% in Assin Foso and 50.0% in
Twifo Praso. The distribution of the two alleles; wild
type (K76) and mutant type (T76) from the four study
sites is shown in Table. Significant association was found
between prevalence of CQ stocks and prevalence of pfcrt
T76 mutant allele in all the study sites, except Twifo
Praso as shown in Figure 1. Additionally, the levels of
CQ usage within a study site were significantly associ-
ated with the prevalence of pfcrt T76 mutant allele. In
Cape Coast and Assin Foso, a high number of partici-
pants (23.21 and 18.88% respectively) had CQ in their
urine samples, and higher prevalence of pfcrt T76shops that had CQ stocks at the study sites
rcentage of subjects with
CQ in urine (n/N)
Percentage of drug shops
with CQ stocks (n/N)
23.21 (13/56) 21.05 (4/19)
11.43 (12/105) 9.09 (1/13)
18.88 (27/143) 16.67 (3/19)
16.43 (23/140) 10.53 (2/19)
16.89 (75/444) 14.49 (10/69)
Figure 1 Association between chloroquine stocking in a community and prevalence of K76T of pfcrt K76T mutation. The % of community
pharmacies and chemical shops that are still stocking and selling chloroquine in the study communities.
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pared to Elmina (p = 0.023) and Twifo Praso (p = 0.01) as
shown in Figure 2.
The study also demonstrated that individuals who stay
in an area where community pharmacies and chemical
shops had CQ stocks have five times more risk of be-
come infected with T76 resistant P. falciparum strain
than individuals who stay in CQ free area [RR = 0.20,
95% CI (0.11-0.34), p < 0.001]. As shown in Figure 1,
there was significant association between CQ stock
within the communities and T76 mutation except Twifo
Praso. Cape Coast had the highest number of commu-
nity pharmacies and chemical shops that stocked CQand the risk of individuals becoming infected with T76
resistant mutant is 26% [RR = 0.26, 95% CI (0.11-0.63),
p < 0.001] while individuals staying in Elmina, study site
with the least number of community pharmacies and
chemical shops stocking CQ had 10% risks of becoming
infected with T76 resistant mutant [RR = 0.10, 95% CI
(0.02-0.66), p < 0.05]. Again, individuals who still use CQ
for malaria treatment had thirteen times more risks of
harbouring T76 resistant mutant P. falciparum strain
compared to individuals who do not use CQ [OR = 0.08,
95% CI (0.05-0.12), p < 0.001]. The risk of stocking CQ
in an area or using CQ and becoming infected with P.
falciparum with T76 mutation is shown in Table 3. CQ
Figure 2 Association between urine chloroquine levels and prevalence of K76T of pfcrt K76T mutation in the study sites. The % urine
chloroquine indicates the prevalence of chloroquine use among the study subjects.
Table 3 Association between CQ stocks and/or CQ in urine and the risk of acquiring infection with CQ resistant
P. falciparum strains
Study sites CQ stocks and prevalence of T76 mutation of pfcrt Urine CQ and prevalence of T76 mutation of pfcrt
RR 95% CI OR 95% CI
Cape Coast 0.26 (0.11-0.63)HS 0.07 (0.03-0.18)HS
Elmina 0.10 (0.02-0.66)S 0.04 (0.02-0.11)HS
Twifo Praso 0.21 (0.06-0.80)S 0.19 (0.09-0.39)HS
Assin Foso 0.22 (0.08-0.62)HS 0.06 (0.03-0.12)HS
HS = highly significant (p < 0.001).
S = significant (p < 0.05).
NS = not significant (p > 0.05).
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T76 mutation in all the study sites (Figure 2).
Discussion
Various studies since the change in malaria treatment
policy in Ghana have reported different levels in preva-
lence of the mutant pfcrt T76 in P. falciparum isolates
collected from different parts of the country [4,5,16]. CQ
pressure is driven by high CQ usage in an area and it is
a major determinant of selection and spread of CQ re-
sistance genes among P. falciparum population [17-19].
The persistent treatment of P. falciparum infections with
CQ will subsequently encourage the selection of CQ
resistant strains [20-23]. The danger is that there could
be subsequent selection of additional changes in genes
regulating P. falciparum response to CQ [24-28]. Such a
situation will favour cross-resistance between CQ and
amodiaquine, which is co-partner of artesunate, the first
ACT deployed in Ghana [28-30].
In this study, the risks of becoming infected with T76
mutant of pfcrt gene of P. falciparum isolates was strongly
associated with staying at a place where community phar-
macies and chemical shops stock CQ for sale or where
there is CQ usage. This observation is supported by sev-
eral field studies in different geographical sites that have
shown absolute specificity of pfcrt T76 molecular marker
to predict CQ resistance both in vitro and in vivo [31,32].
The high prevalence of the pfcrt T76 mutation recorded
in this study after eight years of discontinuous usage of
CQ in Ghana is an indication of circulation of CQ resist-
ant strains. The transmission of the T76 mutant of pfcrt
gene is possible in the study areas because it has been
shown elsewhere that there is a high gametocyte carriage
and infectivity of resistant parasites by mosquitoes than
the drug sensitive types [33,34]. The detection of traces of
CQ in the urine samples of study subjects confirms CQ
usage, a factor responsible for the development of CQ
resistance. It is, therefore, speculated that CQ usage and
not AS-AQ combination usage that selects pfcrt T76
resistance. The observed high prevalence of the pfcrt T76
mutation is similar to the Uganda study where CQ
was substituted with artemether-lumefantrine (AL) as
the first-line anti-malarial drug [35,36]. After seven years
of AL usage, CQ resistance was still high, ranging from
98.7 to 100% [35,36]. The increase in the observed re-
sistance in those reports was attributed to continuous
use of CQ, the same reason adduced by this study. In
support of this speculation are two separate reports
that did not find any association between pfcrt T76
and sulphadoxine-pyrimethamine-amodiaquine combi-
nation in treatment failure after four years [37] as
well as pfcrt T76 in vitro resistance studies after eight
years of using amodiaquine combination at Pikine,
Senegal [38].It has been demonstrated in this study that the level of
CQ stocking and usage is significantly associated with
the prevalence of pfcrt T76 mutation within a study
site. This support the argument that emergence of CQ re-
sistance is influenced by intensity of CQ usage [39-42].
The mutations in pfcrt have been identified to confer and
improve the fitness and stability of parasites containing
the T76 mutation [43,44]. The detection of high preva-
lence of some point mutations of pfmdr1 in Central region
of the country (unpublished data) also augments the
fitness and stability of CQ resistant P. falciparum strains
in the study sites. The current high prevalence of pfcrt
threatens anti-malarial treatment policy in the country.
Since mutations in pfcrt have shown to confer resistance
to amodiaquine which co-partners artesunate in the com-
bination therapy as first line malaria treatment regimen in
the country, it is important to constantly monitor the effi-
cacy of all ACT regimen especially amodiaquine-based
ACT for early detection of P. falciparum resistance
[16,26,32,45-48]. Also the level of quinine and amo-
diaquine resistance [5] as well as treatment failures with
artesunate + amodiaquine in the country requires constant
monitoring.
The differences in the distribution of pfcrt T76 resistance
gene among the four study sites were constantly related to
the different pattern of CQ stocking and usage in each
area. This suggests that complete withdrawal of CQ from
the country could lead to re-emergences of CQ sensitive
P. falciparum similar to the findings from other endemic
countries [35,36,49,50].
The reason for stocking CQ by community pharmacies
and chemical shops was unknown, however CQ is cheaper
and this may account for people patronizing [51,52] it
after its ban. Additionally, subjects who have strong
perceptions about the efficacy and efficiency of CQ for
malaria treatment [51-53] still patronized it. Therefore,
switching from CQ to ACTs has become very difficult for
them. Other studies conducted in various parts of Ghana
and other countries also indicated the continuous usage of
CQ [53-55].Conclusion
The findings gave evidence that the significant variations
in pfcrt T76 of P. falciparum isolates in some parts of
Ghana are highly associated with the sale and use of CQ
in these communities.
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